Search

Your search keyword '"Sobue, G."' showing total 1,622 results
Start Over Author "Sobue, G."
1,622 results on '"Sobue, G."'

1. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial

Author

Misawa, S, Kuwabara, S, Sato, Y, Yamaguchi, N, Nagashima, K, Katayama, K, Sekiguchi, Y, Iwai, Y, Amino, H, Suichi, T, Yokota, T, Nishida, Y, Kanouchi, T, Kohara, N, Kawamoto, M, Ishii, J, Kuwahara, M, Suzuki, H, Hirata, K, Kokubun, N, Masuda, R, Kaneko, J, Yabe, I, Sasaki, H, Kaida, K, Takazaki, H, Suzuki, N, Suzuki, S, Nodera, H, Matsui, N, Tsuji, S, Koike, H, Yamasaki, R, Kusunoki, S, Nagashima, T, Shimizu, T, Hirotani, M, Kadoya, M, Nakahara, J, Shimizu, J, Tanaka, M, Sobue, G, Katsuno, M, Yamaguchi, H, Ogata, H, Misawa, Sonoko, Kuwabara, Satoshi, Sato, Yasunori, Yamaguchi, Nobuko, Nagashima, Kengo, Katayama, Kanako, Sekiguchi, Yukari, Iwai, Yuta, Amino, Hiroshi, Suichi, Tomoki, Yokota, Takanori, Nishida, Yoichiro, Kanouchi, Tadashi, Kohara, Nobuo, Kawamoto, Michi, Ishii, Junko, Kuwahara, Motoi, Suzuki, Hidekazu, Hirata, Koichi, Kokubun, Norito, Masuda, Ray, Kaneko, Juntaro, Yabe, Ichiro, Sasaki, Hidenao, Kaida, Ken-ichi, Takazaki, Hiroshi, Suzuki, Norihiro, Suzuki, Shigeaki, Nodera, Hiroyuki, Matsui, Naoko, Tsuji, Shoji, Koike, Haruki, Yamasaki, Ryo, and Kusunoki, Susumu

Published
2018
Full Text
View/download PDF

2. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Author

Merkies, I.S.J., van Schaik, I.N., Bril, V., Hartung, H.P., Lewis, R.A., Sobue, G., Lawo, J.P., Mielke, O., Cornblath, D.R., RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, and Klinische Neurowetenschappen

Subjects
I-RODS, chronic inflammatory demyelinating polyneuropathy, General Neuroscience, SCORE, SUM, Neurology (clinical), CIDP, IgPro20, subcutaneous immunoglobulin, RODS, SCIG, INCAT
Abstract

Clinical trials in chronic inflammatory demyelinating polyneuropathy (CIDP) often assess efficacy using the ordinal Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. Here, data from the PATH study was reanalyzed using change in Inflammatory Rasch-built Overall Disability Scale (I-RODS) to define CIDP relapse instead of INCAT. The PATH study comprised an intravenous immunoglobulin (IVIG) dependency period and an IVIG (IgPro10 [Privigen]) restabilization period; subjects were then randomized to weekly maintenance subcutaneous immunoglobulin (SCIG; IgPro20 [Hizentra]) 0.2 g/kg or 0.4 g/kg or placebo for 24 weeks. CIDP relapse was defined as >= 1-point deterioration in adjusted INCAT, with a primary endpoint of relapse or withdrawal rates. This retrospective exploratory analysis redefined relapse using I-RODS via three different cut-off methods: an individual variability method, fixed cut-off of >= 8-point deterioration on I-RODS centile score or >= 4-point deterioration on I-RODS raw score. Relapse or withdrawal rates were 47% for placebo, 34% for 0.2 g/kg IgPro20 and 19% for 0.4 g/kg IgPro20 using the raw score; 40%, 28% and 15%, respectively using the centile score, and 49%, 40% and 27%, respectively using the individual variability method. IgPro20 was shown to be efficacious as a maintenance therapy for CIDP when relapse was defined using I-RODS. A stable response pattern was shown for I-RODS across various applied cut-offs, which could be applied in future clinical trials.

Published
2022

4. Severe brain atrophy in the elderly as a risk factor for lower respiratory tract infection

Author

Okada R, Okada T, Okada A, Muramoto H, Katsuno M, Sobue G, and Hamajima N

Subjects
brain atrophy, dysphagia, elderly, pneumonia, respiratory infection, white matter lesions, Geriatrics, RC952-954.6
Abstract

Rieko Okada,1 Takashi Okada,2 Akira Okada,2 Hideyuki Muramoto,3 Masahisa Katsuno,4 Gen Sobue,4 Nobuyuki Hamajima11Department of Preventive Medicine, Nagoya University Graduate School of Medicine, 2Okada Medical Clinic, 3Muramoto Clinic, 4Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, JapanBackground: The purpose of this study is to determine whether elderly subjects with severe brain atrophy, which is associated with neurodegeneration and difficulty swallowing (dysphagia), are more susceptible to lower respiratory tract infections (LRTI), including pneumonia.Methods: The severity of brain atrophy was assessed by computed tomography in 51 nursing home residents aged 60–96 years. The incidence of LRTI, defined by body temperature ≥ 38.0°C, presence of two or more respiratory symptoms, and use of antibiotics, was determined over 4 years. The incidence of LRTI was compared according to the severity and type of brain atrophy.Results: The incidence rate ratio of LRTI was significantly higher (odds ratio 4.60, 95% confidence interval 1.18–17.93, fully adjusted P = 0.028) and the time to the first episode of LRTI was significantly shorter (log-rank test, P = 0.019) in subjects with severe brain atrophy in any lobe. Frontal and parietal lobe atrophy was associated with a significantly increased risk of LRTI, while temporal lobe atrophy, ventricular dilatation, and diffuse white matter lesions did not influence the risk of LRTI.Conclusion: Elderly subjects with severe brain atrophy are more susceptible to LRTI, possibly as a result of neurodegeneration causing dysphagia and silent aspiration. Assessing the severity of brain atrophy might be useful to identify subjects at increased risk of respiratory infections in a prospective manner.Keywords: brain atrophy, dysphagia, elderly, pneumonia, respiratory infection, white matter lesions

Published
2012

5. Biochemical Characterization of the Nerve Growth Factor Receptor in Neural-Related Tumors

Author

Ross, A. H., Sobue, G., Hotta, H., Reddy, U. R., Compans, R. W., editor, Cooper, M., editor, Koprowski, H., editor, McConnell, I., editor, Melchers, F., editor, Nussenzweig, V., editor, Oldstone, M., editor, Olsnes, S., editor, Potter, M., editor, Saedler, H., editor, Vogt, P. K., editor, Wagner, H., editor, Wilson, I., editor, and Bothwell, Mark, editor

Published
1991
Full Text
View/download PDF

12. Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndrome

Author

Koike, H., Iijima, M., Mori, K., Yamamoto, M., Hattori, N., Watanabe, H., Tanaka, F., Doyu, M., and Sobue, G.

Subjects
Peripheral nerve diseases -- Development and progression, Peripheral nerve diseases -- Research, Cytokines -- Physiological aspects, Cytokines -- Research, Myelinated neurofibrils -- Physiological aspects, Myelinated neurofibrils -- Research, Health, Psychology and mental health
Published
2008

14. Cognitive impairment in spinocerebellar ataxia type 6

Author

Suenaga, M., Kawai, Y., Watanabe, H., Atsuta, N., Ito, M., Tanaka, F., Katsuno, M., Fukatsu, H., Naganawa, S., and Sobue, G.

Subjects
Cognition disorders -- Research, Cognition disorders -- Physiological aspects, Ataxia -- Research, Ataxia -- Physiological aspects, Neuropsychological tests -- Usage, Health, Psychology and mental health
Published
2008

15. Age associated axonal features in HNPP with 17p11.2 deletion in Japan

Author

Koike, H., Hirayama, M., Yamamoto, M., Ito, H., Hattori, N., Umehara, F., Arimura, K., Ikeda, S., Ando, Y., Nakazato, M., Kaji, R., Hayasaka, K., Nakagawa, M., Sakoda, S., Matsumura, K., Onodera, O., Baba, M., Yasuda, H., Saito, T., Kira, J., Nakashima, K., Oka, N., and Sobue, G.

Subjects
Peripheral nerve diseases -- Development and progression, Clinical pathology -- Observations, Age -- Observations, Health, Psychology and mental health
Published
2005

17. Multiple regional [.sup.1]H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker

Author

Watanabe, H., Fukatsu, H., Katsuno, M., Sugiura, M., Hamada, K., Okada, Y., Hirayama, M., Ishigaki, T., and Sobue, G.

Subjects
Health, Psychology and mental health
Abstract

J Neurol Neurosurg Psychiatry 2004;75:103-109 Objective: We performed [.sup.1]H-MR spectroscopy ([.sup.1]H-MRS) on multiple brain regions to determine the metabolite pattern and diagnostic utility of [.sup.1]H-MRS in multiple system atrophy (MSA). [...]

Published
2004

18. Sequential constriction of upper airway and vocal cords in sleep apnoea of multiple system atrophy: low field magnetic resonance fluoroscopic study. (Short Report)

Author

Hirayama, M., Fukatsu, H., Watanabe, H., Koike, Y., Noda, A., Ito, H., Kobayashi, R., and Sobue, G.

Subjects
Methodology -- Research, Sleep apnea syndromes -- Research, Health, Psychology and mental health, Research
Abstract

Low field magnetic resonance fluoroscopy was used to clarify temporal and spatial features of airway obstruction in sleep apnoea syndrome (SAS) in multiple system atrophy (MSA), as well as in [...]

Published
2003

19. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. (Paper)

Author

Abe, Y., Kachi, T., Kato, T., Arahata, Y., Yamada, T., Washimi, Y., Iwai, K., Ito, K., Yanagisawa, N., and Sobue, G.

Subjects
Patients -- Care and treatment, Parkinson's disease -- Research, Health, Psychology and mental health, Research, Methods
Abstract

Objective: The purpose of this study was to analyse changes in regional cerebral blood flow (rCBF) in Parkinson's disease (PD) without dementia. Methods: Twenty eight non-demented patients with PD and [...]

Published
2003

20. Onset age and severity of motor impairment are associated with reduction of myocardial [I.sup.123]-MIBG uptake in Parkinson's disease. (Paper)

Author

Hamada, K., Hirayama, M., Watanabe, H., Kobayashi, R., Ito, H., Ieda, T., Koike, Y., and Sobue, G.

Subjects
Patients -- Care and treatment, Parkinson's disease -- Care and treatment, Health, Psychology and mental health, Care and treatment, Methods
Abstract

Objectives: To elucidate the factors associated with severity of cardiac sympathetic nerve involvement in idiopathic Parkinson's disease (PD). Methods: [I.sup.123]-metaiodobenzylguanidine uptake was examined in 88 patients with PD. The ratio [...]

Published
2003

27. 20. Practical application of subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy – results from a multicenter, randomized, double-blind, placebo-controlled trial (The PATH Study)

Author

Schaik, I.N., primary, Bril, V., additional, Geloven, N., additional, Hartung, H.P., additional, Lewis, R.A., additional, Sobue, G., additional, Lawo, J.P., additional, Mielke, O., additional, Durn, B.L., additional, Cornblath, D.R., additional, Merkies, I.S.J., additional, and Dimachkie, M.M., additional

Published
2020
Full Text
View/download PDF

43. Placebo effect in chronic inflammatory demyelinating polyneuropathy: ThePATHstudy and a systematic review

Author

Lewis, RA, Cornblath, DR, Hartung, H-P, Sobue, G, Lawo, J-P, Mielke, O, Durn, BL, Bril, V, Merkies, ISJ, Bassett, P, Cleasby, A, van Schaik, IN, Lewis, RA, Cornblath, DR, Hartung, H-P, Sobue, G, Lawo, J-P, Mielke, O, Durn, BL, Bril, V, Merkies, ISJ, Bassett, P, Cleasby, A, and van Schaik, IN

Abstract

The Polyneuropathy And Treatment with Hizentra (PATH) study required subjects with chronic inflammatory demyelinating polyneuropathy (CIDP) to show dependency on immunoglobulin G (IgG) and then be restabilized on IgG before being randomized to placebo or one of two doses of subcutaneous immunoglobulin (SCIG). Nineteen of the 51 subjects (37%) randomized to placebo did not relapse over the next 24 weeks. This article explores the reasons for this effect. A post-hoc analysis of the PATH placebo group was undertaken. A literature search identified other placebo-controlled CIDP trials for review and comparison. In PATH, subjects randomized to placebo who did not relapse were significantly older, had more severe disease, and took longer to deteriorate in the IgG dependency period compared with those who relapsed. Published trials in CIDP, whose primary endpoint was stability or deterioration, had a mean non-deterioration (placebo effect) of 43%, while trials with a primary endpoint of improvement had a placebo response of only 11%. Placebo is an important variable in the design of CIDP trials. Trials designed to show clinical improvement will have a significantly lower effect of this phenomenon than those designed to show stability or deterioration.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results